Evidence map›Paper›PMID 32385576›Full record

Observational studyJournal of neural transmission (Vienna, Austria : 1996)2020

Creation of a gene expression classifier for predicting Parkinson's disease rate of progression.

Jose Martin Rabey, Jennifer Yarden, Nir Dotan, Danit Mechlovich, Peter Riederer, Moussa B H Youdim

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of neural transmission (Vienna, Austria : 1996), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Differential expression ofFrontiers in molecular neuroscience · 2023
    Article
  5. Review
  6. Treatment; Moussa B.H. Youdim.Journal of neural transmission (Vienna, Austria : 1996) · 2022
    Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 3 countries.

Jose Martin RabeyBioShai Ltd., 1 Ha-Tsmikha St., Yokneam, Israel. Jmrabey@yahoo.com.
Jennifer YardenBioShai Ltd., 1 Ha-Tsmikha St., Yokneam, Israel.
Nir DotanBioShai Ltd., 1 Ha-Tsmikha St., Yokneam, Israel.
Danit MechlovichBioShai Ltd., 1 Ha-Tsmikha St., Yokneam, Israel.
Peter RiedererBioShai Ltd., 1 Ha-Tsmikha St., Yokneam, Israel.
Moussa B H YoudimBioShai Ltd., 1 Ha-Tsmikha St., Yokneam, Israel.
Technion – Israel Institute of Technology · ILUniversity of Southern Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) etiology is heterogeneous, genetic, and multi-factorial, resulting in a varied disease from a mild slow progression to a more severe rapid progression. Prognostic information on the nature of the patient's disease at diagnosis aids the physician in counseling patients on treatment options and life planning. In a cohort of PD patients from the PPMI study, the relative gene expression levels of SKP1A, UBE2K, ALDH1A1, PSMC4, HSPA8 and LAMB2 were measured in baseline blood samples by real-time quantitative PCR. At baseline PD patients were up to 2 years from diagnosis, H&Y scale ≤ 2 and PD treatment naïve. PD-Prediction algorithm comprised of ALDH1A1, LAMB2, UBE2K, SKP1A and age was created by logistic regression for predicting progression to ≤ 70% Modified Schwab and England Activities of Daily Living (S&E-ADL). In relation to patients negative for PD-Prediction (n = 180), patients positive (n = 30) for Cutoff-1 (at 82% specificity, 80.0% sensitivity) had positive hazard ratio (HR+) of 10.6 (95% CI, 2.2-50.1), and positive (n = 23) for Cutoff-2 (at 93% specificity, 47% sensitivity) had HR+ of 17.1 (95% CI, 3.2-89.9) to progress to ≤ 70% S&E-ADL within 3 years (P value < 0.0001). Likewise, patients positive for PD-Prediction Cutoff-1 (n = 49) had HR+ 4.3 (95% CI, 1.6-11.6) for faster time to H&Y 3 in relation to patients negative (n = 170) for PD-Prediction (P value = 0.0002). Our findings show an algorithm that seems to predict fast PD progression and may potentially be used as a tool to assist the physician in choosing an optimal treatment plan, improving the patient's quality of life and overall health outcome.

Indexed as

Disease ProgressionAdultAgedAged, 80 and overBiomarkersFemaleGene ExpressionHumansLongitudinal StudiesMaleMiddle AgedParkinson DiseasePrognosisSensitivity and SpecificityBiomarkersBiomarkerGene expression classifierHoehn and YahrModified Schwab and England Activities of Daily LivingParkinson’s diseasePrognosis

Identifiers

PMID32385576
OpenAlexW3022760140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.